Clinical Study of Chimeric CD(Cluster of Differentiation)133 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Malignancies
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Occurrence of study related adverse events
研究概览
简要总结
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with Relapsed and/or Chemotherapy Refractory Advanced Malignancies.
详细描述
I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-CD133 (cluster of differentiation antigen 133 ) vector (referred to as CART-133 cells).
II. Determine duration of in vivo survival of CART-133 cells. RT-PCR (reverse transcription polymerase chain reaction) analysis of whole blood will be used to detect and quantify survival of CART-133 TCR (T-cell receptor) zeta:CD137 and TCR zeta cells over time.
SECONDARY OBJECTIVES:
I. For patients with detectable disease, measure anti-tumor response due to CART-133 cell infusions.
II. To determine if the CD137 transgene is superior to the TCR zeta only transgene as measured by the relative engraftment levels of CART-133 TCR zeta:CD137 and TCR zeta cells over time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chemotherapy refractory or relapsed CD133-positive liver cancer, pancreatic cancer, brain tumor ,breast cancer, ovarian tumors, colorectal cancer and acute leukemia.
- •Patients must be 18 years of age or older.
- •Patients must have an ECOG (Eastern Cooperative Oncology Group )performance status of 0-
- •Patients must have evidence of adequate bone marrow reserve, hepatic and renal function as evidenced by the following laboratory parameters:
- •Absolute neutrophil count greater than 1500/mm
- •Platelet count greater than 100,000/mm
- •Hemoglobin greater than 10g/dl (patients may receive transfusions to meet this parameter).
- •Total bilirubin < 1.5 times upper limits of normal. Serum creatinine less than or equal to 1.6 mg/ml or the creatinine clearance must be greater than 70 ml/min/1.73m.
- •Seronegative for HIV antibody.
- •Seronegative for active hepatitis B, and seronegative for hepatitis C antibody.
- •Patients must be willing to practice birth control during and for four months following treatment. NOTE: women of child-bearing age must have evidence of negative pregnancy test.
- •Patients must be willing to sign an informed consent.
排除标准
- •Patients with life expectancy less than 12 months will be excluded.
- •Patients with uncontrolled hypertension (> 160/95), unstable coronary disease evidenced by uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (> New York Heart Association Class II), or myocardial infarction within 6 months of study will be excluded.
- •Patients with any of the following pulmonary function abnormalities will be excluded: FEV(forced expiratory volume), < 30% predicted; DLCO (diffusing capacity of lung for carbon monoxide) < 30% predicted (post-bronchodilator); Oxygen Saturation less than 90% on room air.
- •Patients with severe liver and kidney dysfunction or consciousness disorders will be excluded.
- •Pregnant and/or lactating women will be excluded.
- •Patients with active infections, including HIV, will be excluded, due to unknown effects of the vaccine on lymphoid precursors.
- •Patients with any type of primary immunodeficiencies will be excluded from the study.
- •Patients requiring corticosteroids (other than inhaled) will be excluded.
- •Patients with history of T cell tumors will be excluded.
- •Patients who are participating or participated any other clinical trials in latest 30 days will be excluded.
- •Patients with relapsed acute leukemia after allogeneic stem cell transplantation
结局指标
主要结局
Occurrence of study related adverse events
时间窗: Until week 24
defined as \>= Grade 3 signs/symptoms, laboratory toxicities, and clinical
次要结局
- Anti-tumor responses to CART-133 cell infusions(up to 24 weeks)
研究者
Han weidong
PI
Chinese PLA General Hospital